Fact Source: Financial Supervisory Service DART / 2025-04-23
Disclosure Type: Tentative Operating Performance based on Consolidated Financial Statements (Fair Disclosure)
💡 3-Second Summary
SAMSUNG BIOLOGICS recorded a stellar performance for Q1 2025, posting approximately KRW 1.3T in revenue and KRW 486.7B in operating profit, translating to a YoY increase of 37.11% and 119.92%, respectively.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Q1 2025 Consolidated Tentative Performance (Unit: KRW):
- Revenue: KRW 1,298,273,000,000 (KRW 1.298T)
- Compared to Previous Quarter (Q4 2024): +3.33%
- Compared to Same Period Last Year (Q1 2024): +37.11%
- Operating Profit: KRW 486,689,000,000 (KRW 486.7B)
- Compared to Previous Quarter (Q4 2024): +49.45%
- Compared to Same Period Last Year (Q1 2024): +119.92%
- Income Before Income Tax Expenses: KRW 499,387,000,000 (KRW 499.4B)
- Compared to Same Period Last Year: +108.01%
- Net Income (Controlling Interest): KRW 375,554,000,000 (KRW 375.6B)
- Compared to Same Period Last Year: +109.38%
- Revenue: KRW 1,298,273,000,000 (KRW 1.298T)
- Note: The disclosure filing does not provide the specific qualitative causes or drivers behind this growth. These figures are tentative and have not yet been audited by an external auditor, meaning they remain subject to change.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
SAMSUNG BIOLOGICS’ Q1 2025 tentative earnings highlight a significant upward shift in the company’s baseline profitability and fundamental strength. Historically, the first quarter is considered a seasonally slow period for the bio-industry. Defying this seasonality by achieving simultaneous expansions in both top-line revenue (3.33%) and operating profit (49.45%) compared to Q4 2024 signals robust operational momentum. The operating profit margin reached an impressive 37.48%, indicating that operating leverage from massive production assets is functioning efficiently.
The fact that operating profit jumped more than twofold (119.92%) on a year-over-year basis provides a powerful reassurance to long-term shareholders. Additionally, data validation confirms that the top-line revenue comfortably exceeds the operating profit line, verifying the accounting layout’s integrity.
However, since this filing lacks detailed disclosures on the exact catalysts behind this earnings surprise—such as exact plant utilization rates, foreign exchange tailwinds, or individual subsidiary contributions—investors should cross-reference these metrics with the comprehensive IR presentation material to be uploaded to the corporate website to evaluate the underlying quality of this growth.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS absolutely crushed it in Q1, a period typically feared for seasonal slow downs! Operating profit exploded by nearly 120% compared to Q1 last year. This is not just a standard recovery; it is an absolute blowout. Pulling in KRW 1.3T in revenue and translating that into nearly KRW 500B in pure operating profit demonstrates stellar commercial efficiency.
Although the corporate filing remains silent on the exact narrative behind this surge, the numbers tell the whole story. With operating profit surging nearly 50% sequentially against the previous quarter, it strongly implies that the manufacturing lines are humming at full throttle. These numbers are tentative pending a final audit, but the massive scale of this surprise provides strong ammunition for institutional buying waves to drive upward momentum!
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
